Canon faces up to $2.9B fine for breaking EU merger rules

While the European Commission is investigating Canon for acquiring Toshiba Medical Systems before obtaining approval, the merger will not be affected.

Canon is facing a fine of up to 10% of annual revenues from the European Commission for jumping the gun on its deal to acquire Toshiba’s medical imaging business.

The EC is calling Canon out for completing its $6 billion acquisition of the Toshiba unit before getting approval. Canon reported (PDF) $29.3 billion in sales during fiscal 2016. While Canon may have to cough up a $2.9 billion penalty, the European Union said in a statement that its investigation will not affect its approval of the merger, which was given in September 2016.

The commission said Canon used a two-step “warehousing” deal to take over Toshiba Medical Systems before securing approval for the merger.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

In the first step, the EC said, an interim buyer picked up 95% of Toshiba Medical Systems shares, while Canon bought the remaining 5%. Canon also paid for options over the interim buyer’s stake. In the second step, Canon exercised its share options, thereby acquiring 100% of the shares.

In July, Japanese regulators OK’d the deal but voiced concerns that Canon potentially violated the law.

The European Commission sent complaints to three other companies, Bloomberg reported, including Merck KGaA and GE. They could be fined up to 1% of global sales for failing to provide information or giving misleading information.

"We need companies to work with us to ensure fast and predictable merger control, to the benefit of both companies and consumers,” said Commissioner Margrethe Vestager in the statement. “But we can only do our job well if we can rely on cooperation from the companies concerned—they must obtain our approval before they implement their transactions and the information they supply us must be correct and complete."

Suggested Articles

The response rate was lower in the ONCOS-102 arm than the control cohort, but Targovax saw positives elsewhere.

The €13.9 million series B round will fund a phase 1/2 trial of a therapeutic vaccine in patients with non-small cell lung cancer.

Precision oncology firm Notable Labs is launching its first self-sponsored clinical trial, designed from the ground up to help validate its platform.